NASDAQ:CDNA

CareDx (CDNA) Stock Price, News & Analysis

CareDx logo
$74.44 -0.12 (-0.16%)
Closing price 04:00 PM Eastern
Extended Trading
$74.46 +0.02 (+0.03%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About CareDx Stock (NASDAQ:CDNA)

Advanced

Key Stats

Today's Range
$72.32
▼
$75.58
50-Day Range
$50.02
▼
$88.47
52-Week Range
$15.56
▼
$90.87
Volume
537,257 shs
Average Volume
1.30 million shs
Market Capitalization
$3.91 billion
P/E Ratio
112.97
Dividend Yield
N/A
Price Target
$70.33
Consensus Rating
Moderate Buy

Company Overview

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time.

Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

The company traces its roots to XDx, founded in 1998, and adopted the CareDx name in 2010. It serves transplant centers and patients in the United States and other markets.

AI Generated. May Contain Errors.

CareDx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

CDNA MarketRank™: 
1.34935680433 of 5 stars

CareDx scored higher than 27% of companies evaluated by MarketBeat, and ranked 1469th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 4 buy ratings, 4 hold ratings, and no sell ratings.

  • Downside Risk

    CareDx has a consensus price target of $70.33, representing about 5.5% downside from its current price of $74.44.

  • Amount of Analyst Coverage

    CareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CareDx's stock forecast and price target.
  • Earnings Growth

    Earnings for CareDx are expected to decrease by -18.00% in the coming year, from $1.00 to $0.82 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CareDx is 112.97, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.91.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CareDx is 112.97, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.58.

  • Price to Book Value per Share Ratio

    CareDx has a P/B Ratio of 8.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.02% of the float of CareDx has been sold short.
  • Short Interest Ratio / Days to Cover

    CareDx has a short interest ratio ("days to cover") of 5.28.
  • Change versus previous month

    Short interest in CareDx has recently increased by 7.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CareDx does not currently pay a dividend.

  • Dividend Growth

    CareDx does not have a long track record of dividend growth.

  • News Sentiment

    CareDx has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for CareDx this week, compared to 4 articles on an average week.
  • Search Interest

    24 people have searched for CDNA on MarketBeat in the last 30 days. This is an increase of 243% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added CareDx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,080,346.00 in company stock.

  • Percentage Held by Insiders

    2.40% of the stock of CareDx is held by insiders.

  • Percentage Held by Institutions

    CareDx has minimal institutional ownership at this time.

  • Read more about CareDx's insider trading history.
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CDNA Stock News Headlines

CareDx (NASDAQ:CDNA) CFO Sells $166,271.13 in Stock
CareDx Earnings Call Signals Growth and Pipeline Momentum
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
See More Headlines

CDNA Stock Analysis - Frequently Asked Questions

CareDx's stock was trading at $18.84 on January 1st, 2026. Since then, CDNA shares have increased by 295.1% and is now trading at $74.44.

CareDx, Inc. (NASDAQ:CDNA) released its quarterly earnings results on Thursday, October, 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.45. The company's revenue was up 39.3% compared to the same quarter last year.
Read the conference call transcript
.

CareDx (CDNA) raised $64 million in an initial public offering (IPO) on Thursday, July 17th 2014. The company issued 4,000,000 shares at a price of $15.00-$17.00 per share.

CareDx's top institutional shareholders include State Street Corp (4.99%), Bamco Inc. NY (2.85%), Gagnon Securities LLC (2.04%) and Goldman Sachs Group Inc. (1.77%). Insiders that own company stock include John Walter Hanna Jr, Abhishek Jain, Peter Maag, Alexander L Johnson, Keith Kennedy, George Bickerstaff, William A Hagstrom, Michael Goldberg, Christine Cournoyer and Hannah Valantine.
View institutional ownership trends
.

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (XYZ), Tesla (TSLA), Alibaba Group (BABA) and PayPal (PYPL).

Company Calendar

Last Earnings
10/29/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CDNA
CIK
1217234
Employees
765
Year Founded
2000

Price Target and Rating

High Price Target
$100.00
Low Price Target
$21.00
Potential Upside/Downside
-5.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.39
Trailing P/E Ratio
112.97
Forward P/E Ratio
90.78
P/E Growth
N/A
Net Income
-$21.35 million
Net Margins
25.86%
Pretax Margin
24.98%
Return on Equity
9.74%
Return on Assets
7.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.31
Quick Ratio
2.25

Sales & Book Value

Annual Sales
$379.80 million
Price / Sales
10.30
Cash Flow
$0.01 per share
Price / Cash Flow
11,447.17
Book Value
$8.90 per share
Price / Book
8.36

Miscellaneous

Outstanding Shares
52,540,000
Free Float
51,282,000
Market Cap
$3.91 billion
Optionable
Optionable
Beta
2.51

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:CDNA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners